Please assess the completion status of the following clinical trial:

Trial Title: Nesiritide Use Following Cardiac Surgery in Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 48 hours after cardiac surgery requiring cardiopulmonary bypass~* \< 1 year of age~* Receiving chlorothiazide and furosemide for \> 12 hours~* Urine output \< 4 cc/kg/hour, or fluid intake \> output for 2 consecutive days~* Receiving mechanical ventilation~* Presence of body wall edema on CXR, defined as a radiologic index of \> 2~* Plan for \> 24 hrs further diuresis before chest closure or extubation~Exclusion Criteria:~* Age \> 365 days at the time of enrollment~* Corrected estimated gestational age \< 35 weeks at the time of enrollment~* Serum creatinine \> 2.0 mg/dL at the time of enrollment~* Significant hemodynamic instability at the time of enrollment~* Lack of dedicated intravenous access for nesiritide infusion~* Lack of arterial line for continuous blood pressure monitoring~* Lack of a Foley catheter for continuous urine collection~* Enrollment in another research study such that the outcomes of either study may be confounded by participation in this study, or such that the amount of blood drawn for research purposes becomes excessive.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.
- Nesiritide (Type: EXPERIMENTAL): In this crossover pilot study, patients are randomly assigned to receive either nesiritide or placebo infusion for 10 hours, followed by a two hour washout period, and then the other study drug for 10 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).